

Ingo K Mellinghoff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4477506/publications.pdf>

Version: 2024-02-01

90
papers

16,159
citations

71102

41
h-index

49909

87
g-index

91
all docs

91
docs citations

91
times ranked

23255
citing authors

#	ARTICLE	IF	CITATIONS
1	Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. <i>Neuro-Oncology</i> , 2022, 24, 770-778.	1.2	28
2	Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 303-313.	3.4	1
3	Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study. <i>BMC Cancer</i> , 2022, 22, 60.	2.6	5
4	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2022, 24, 855-871.	1.2	38
5	Noninvasive Imaging of CD4+ T Cells in Humanized Mice. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 658-666.	4.1	3
6	Next-generation sequencing of cerebrospinal fluid for clinical molecular diagnostics in pediatric, adolescent and young adult brain tumor patients. <i>Neuro-Oncology</i> , 2022, 24, 1763-1772.	1.2	37
7	GCN2 kinase activation by ATP-competitive kinase inhibitors. <i>Nature Chemical Biology</i> , 2022, 18, 207-215.	8.0	19
8	Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3510-3519.	1.6	7
9	Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab. <i>Npj Breast Cancer</i> , 2022, 8, 37.	5.2	9
10	Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. <i>Neuro-Oncology</i> , 2022, 24, 1219-1229.	1.2	9
11	Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoter. <i>Neuro-Oncology</i> , 2022, 24, 1935-1949.	1.2	165
12	PATH-16. Noninvasive diagnosis of gliomas through CSF cfDNA sequencing in pediatric and adolescent and young adult (AYA) patients. <i>Neuro-Oncology</i> , 2022, 24, i162-i162.	1.2	0
13	Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [64Cu]Cu-NOTA-anti-CD8 PET. <i>Clinical Cancer Research</i> , 2021, 27, 1958-1966.	7.0	21
14	Meningeal lymphatics prime tumor immunity in glioblastoma. <i>Cancer Cell</i> , 2021, 39, 304-306.	16.8	20
15	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	2.1	51
16	GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2074-TPS2074.	1.6	2
17	Prognostic value of [18F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3940-3950.	6.4	8
18	EPCT-21. NEXT-GENERATION SEQUENCING OF CEREBROSPINAL FLUID FOR CLINICAL MOLECULAR DIAGNOSTICS IN ADOLESCENT AND YOUNG ADULT (AYA) BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2021, 23, i51-i51.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. <i>Clinical Cancer Research</i> , 2021, 27, 4491-4499.	7.0	112
20	Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 742-752.	2.8	17
21	Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 36, 95-111.	2.2	6
22	Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 433-444.	2.6	69
23	Pharmacokinetic Assessment of ¹⁸ F-(2 <i>S</i> ,4 <i>R</i>)-4-Fluoroglutamine in Patients with Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 357-366.	5.0	23
24	Histone-Mutant Glioma: Molecular Mechanisms, Preclinical Models, and Implications for Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7193.	4.1	15
25	Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. <i>Acta Neuropathologica Communications</i> , 2020, 8, 186.	5.2	26
26	Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3398-3406.	1.6	167
27	Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 96-103.	3.8	6
28	Prognostic and radiographic correlates of a prospectively collected molecularly profiled cohort of IDH1/2-wildtype astrocytomas. <i>Brain Pathology</i> , 2020, 30, 653-660.	4.1	3
29	Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 101-107.	2.8	99
30	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	1.2	543
31	Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. <i>Neuro-Oncology</i> , 2020, 22, 1822-1830.	1.2	23
32	Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 429-436.	3.7	29
33	Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019, 144, 403-407.	2.9	55
34	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. <i>Clinical Cancer Research</i> , 2019, 25, 5537-5547.	7.0	107
35	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. <i>Nature</i> , 2019, 565, 654-658.	27.8	361
36	Reply to "Assembling the brain trust: the multidisciplinary imperative in neuro-oncology". <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 522-523.	27.6	0

#	ARTICLE	IF	CITATIONS
37	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 741-750.	1.6	103
38	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	27.6	540
39	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	30.7	932
40	ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS. <i>Neuro-Oncology</i> , 2019, 21, vi28-vi29.	1.2	17
41	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. <i>Blood</i> , 2019, 133, 436-445.	1.4	159
42	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
43	Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A. <i>Oncotarget</i> , 2019, 10, 6152-6167.	1.8	14
44	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of ¹⁸ F-(2 <i>S</i> ,4 <i>R</i>)-4-Fluoroglutamine. <i>Radiology</i> , 2018, 287, 667-675.	7.3	80
45	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 295-305.	7.0	68
46	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. <i>Journal of Clinical Oncology</i> , 2018, 36, 1702-1709.	1.6	39
47	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. <i>Cancer Discovery</i> , 2018, 8, 1540-1547.	9.4	138
48	Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. <i>Molecular Systems Biology</i> , 2017, 13, 914.	7.2	73
49	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 1018-1029.	9.4	302
50	Dissecting Glioma Invasiveness in a 3D-Organotypic Model. <i>Trends in Molecular Medicine</i> , 2017, 23, 776-777.	6.7	2
51	EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer. <i>Nature Communications</i> , 2017, 8, 2035.	12.8	23
52	Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. <i>Journal of Neuro-Oncology</i> , 2017, 134, 357-362.	2.9	22
53	Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. <i>Journal of Clinical Oncology</i> , 2016, 34, 2404-2415.	1.6	297
54	MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4. <i>Cell Reports</i> , 2016, 14, 1590-1601.	6.4	174

#	ARTICLE	IF	CITATIONS
55	Prioritization schema for immunotherapy clinical trials in glioblastoma. <i>OncImmunology</i> , 2016, 5, e1145332.	4.6	13
56	Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1837-1842.	7.0	165
57	Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. <i>Neuro-Oncology</i> , 2016, 18, 283-290.	1.2	161
58	Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. <i>JCI Insight</i> , 2016, 1, .	5.0	41
59	Cutaneous adverse drug reaction associated with oral temozolomide presenting as dermal and subcutaneous plaques and nodules. <i>JAAD Case Reports</i> , 2015, 1, 286-288.	0.8	7
60	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. <i>Science Translational Medicine</i> , 2015, 7, 274ra17.	12.4	257
61	T1-Weighted Dynamic Contrast-Enhanced MRI as a Noninvasive Biomarker of Epidermal Growth Factor Receptor vIII Status. <i>American Journal of Neuroradiology</i> , 2015, 36, 2256-2261.	2.4	46
62	Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. <i>Cancer Discovery</i> , 2015, 5, 304-315.	9.4	102
63	IQGAP1 Controls Tight Junction Formation Through Differential Regulation of Claudin Recruitment. <i>Journal of Cell Science</i> , 2015, 128, 853-62.	2.0	18
64	Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7119-7130.	3.0	26
65	PI3K pathway inhibition in GBM–is there a signal?. <i>Neuro-Oncology</i> , 2015, 17, nov124.	1.2	6
66	A correlative optical microscopy and scanning electron microscopy approach to locating nanoparticles in brain tumors. <i>Micron</i> , 2015, 68, 70-76.	2.2	27
67	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	1.2	28
68	A kinase-independent function of AKT promotes cancer cell survival. <i>ELife</i> , 2014, 3, .	6.0	70
69	Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. <i>Neuro-Oncology</i> , 2014, 16, viii7-viii13.	1.2	85
70	Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 5023-5031.	7.0	89
71	ZFH4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State. <i>Cell Reports</i> , 2014, 6, 313-324.	6.4	106
72	Imaging Tumor Burden in the Brain with ⁸⁹ Zr-Transferrin. <i>Journal of Nuclear Medicine</i> , 2013, 54, 90-95.	5.0	33

#	ARTICLE	IF	CITATIONS
73	An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. <i>Science</i> , 2013, 340, 626-630.	12.6	1,014
74	Differential Sensitivity of Glioma- versus Lung Cancer- Specific EGFR Mutations to EGFR Kinase Inhibitors. <i>Cancer Discovery</i> , 2012, 2, 458-471.	9.4	304
75	IDH mutation impairs histone demethylation and results in a block to cell differentiation. <i>Nature</i> , 2012, 483, 474-478.	27.8	1,693
76	Will Kinase Inhibitors Make it as Glioblastoma Drugs?. <i>Current Topics in Microbiology and Immunology</i> , 2011, 355, 135-169.	1.1	22
77	Signal transduction inhibitors and antiangiogenic therapies for malignant glioma. <i>Glia</i> , 2011, 59, 1205-1212.	4.9	28
78	Reply to Parsons: Many tumor types follow the monoclonal model of tumor initiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, E16-E16.	7.1	6
79	Tracing cancer networks with phosphoproteomics. <i>Nature Biotechnology</i> , 2010, 28, 1028-1029.	17.5	16
80	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 6459-6464.	7.1	99
81	Proteasomal and Genetic Inactivation of the NF1 Tumor Suppressor in Gliomagenesis. <i>Cancer Cell</i> , 2009, 16, 44-54.	16.8	132
82	Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma. <i>PLoS Medicine</i> , 2008, 5, e8.	8.4	499
83	Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20007-20012.	7.1	927
84	Why Do Cancer Cells Become "Addicted" to Oncogenic Epidermal Growth Factor Receptor?. <i>PLoS Medicine</i> , 2007, 4, e321.	8.4	5
85	PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2007, 13, 378-381.	7.0	114
86	Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain. <i>PLoS Medicine</i> , 2006, 3, e485.	8.4	298
87	Mammalian Target of Rapamycin Inhibition Promotes Response to Epidermal Growth Factor Receptor Kinase Inhibitors in PTEN-Deficient and PTEN-Intact Glioblastoma Cells. <i>Cancer Research</i> , 2006, 66, 7864-7869.	0.9	231
88	Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. <i>New England Journal of Medicine</i> , 2005, 353, 2012-2024.	27.0	1,376
89	HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. <i>Cancer Cell</i> , 2004, 6, 517-527.	16.8	316
90	The emergence of resistance to targeted cancer therapeutics. <i>Pharmacogenomics</i> , 2002, 3, 603-623.	1.3	26